Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia (Journal article)

Kalambokis, G. N./ Mouzaki, A./ Rodi, M./ Tsianos, E. V.

BACKGROUND: Thrombocytopenia is a major haematological disorder of cirrhosis with unclear pathogenesis. Endotoxaemia resulting from intestinal bacterial overgrowth could reduce platelet counts directly or through cytokine release. AIMS: To correlate endotoxaemia with platelet counts and study the effects of intestinal decontamination with rifaximin on thrombocytopenia in relation to changes in endotoxin and cytokine concentrations in patients with alcoholic cirrhosis. METHODS: Platelet counts, plasma endotoxin levels and serum interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) levels were measured in 23 thrombocytopenic cirrhotic patients (platelet count<150 000/mul) before and after 4-week treatment with rifaximin 1200 mg/d (n = 13) or no treatment (n = 10) and at baseline in 10 cirrhotic patients without thrombocytopenia; spleen size was measured at baseline in all patients. RESULTS: Endotoxin and IL-6 levels were significantly higher in patients with thrombocytopenia than in those without thrombocytopenia (2.76 +/- 0.69 vs. 0.64 +/- 0.09 EU/ml; P < 0.001 and 24.26 +/- 3.38 vs. 2.66 +/- 0.74 pg/ml; P = 0.001 respectively). Platelet counts were inversely correlated with endotoxin levels (r = -0.589; P = 0.003), Child-Pugh score (r = -0.625; P = 0.001), IL-6 levels (r = -0.464; P = 0.02) and spleen size (r = -0.455; P = 0.02) in patients with thrombocytopenia. Following rifaximin, platelet counts increased significantly (83 100 +/- 9700 vs. 99 600 +/- 11 200/mul; P = 0.006) in line with significant reductions in endotoxin (1.28 +/- 0.41 vs. 2.54 +/- 0.86 EU/ml; P = 0.005), IL-1 (3.1 +/- 0.5 vs. 4.4 +/- 1.2 pg/ml; P = 0.04), IL-6 (12.8 +/- 2.5 vs. 21.1 +/- 4.2 pg/ml; P = 0.01) and TNF-alpha (3.6 +/- 1.3 vs. 5.8 +/- 1.7; P = 0.02) levels. Platelet count changes were correlated with the changes in endotoxin (r = 0.573; P = 0.04), TNF-alpha (r = 0.554; P = 0.05) and IL-6 (r = 0.495; P = 0.07) levels. CONCLUSIONS: Rifaximin improves cirrhosis-related thrombocytopenia and this could be related with the reduction of endotoxaemia.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/18557
ISSN: 1478-3231
Link: http://www.ncbi.nlm.nih.gov/pubmed/22098272
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18557
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.